GlassScriptPhysician profile
Barbara Brandt
NPI 1427123686
$3,073.99
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $195 · 2021: $1,069 · 2022: $922.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $800.58 | 2019-2022 | |
| Glaxosmithkline, LLC. | $429.78 | 2019-2022 | |
| Abbvie INC. | $413.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $295.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $248.15 | 2019-2020 | |
| Allergan, INC. | $204.02 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $128.50 | 2019 | |
| Lilly USA, LLC | $114.84 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $96.85 | 2021 | |
| Merck Sharp & Dohme LLC | $17.98 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Brandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.